Recent news coverage includes financial results and operational updates from industry peers and related companies but no direct recent news specifically about NovaBay Pharmaceuticals.

• COPT Defense Properties reported Q3 2026 results with EPS of $0.41 and FFO per share of $0.71 [N1].
• AstraZeneca reported Q3 profit rise and reconfirmed FY26 revenue and core EPS guidance at constant exchange rates [N2].
• Nicox reported narrowing H1 loss due to milestone achievements and lower costs [N3].
• BP reported Q3 RC profit climb and updated FY26 production view [N4].
• Otsuka reported H1 earnings increase and maintained FY26 guidance [N5].
• Three positive social security changes are set to take place in 2027, with two potential negative impacts noted [N6].
• Globant S.A. entered into an amendment to its credit agreement [N7].
• Rocket Lab announced earnings report scheduled for August 10, highlighting a key metric to watch [N8].

The company’s strong liquidity ratios and positive net income for Q3 2026 indicate financial resilience. The reverse stock split may support compliance with exchange listing requirements. These factors could support operational continuity and investor confidence.

Risks include potential security breaches related to self-custody of digital assets, which could materially affect business and financial condition. Anti-dilution provisions in warrants may exert downward pressure on stock price and risk delisting from NYSE American, which could adversely affect stock liquidity and financing options.

Information on NovaBay Pharmaceuticals’ competitive advantages or moat is not explicitly disclosed in the available data. The company’s liquidity position and reported profitability suggest operational stability, but detailed insights into proprietary technology, market position, or barriers to entry are not provided.

• Digital Asset Custody Risk: The company holds a significant portion of its digital assets in self-custody using a single key management platform, exposing it to risks of cyberattack, credential theft, unauthorized transfers, or internal control failures that may result in unrecoverable losses [S2].
• Stock Price Dilution and Listing Risk: Anti-dilution provisions in pre-funded warrants could increase share issuance if stock price falls below $0.85, potentially causing sustained selling pressure and decline in stock price. This may lead to failure to meet NYSE American listing requirements and possible delisting, impacting stock liquidity and financing ability [S2].

• NovaBay Pharmaceuticals, Inc. is a publicly traded company with ticker NBY.
• As of September 30, 2026, the company reported cash and cash equivalents of $7.153 million and current assets of $7.826 million against current liabilities of $0.455 million, resulting in a strong current ratio of 17.2 and cash ratio of 15.72, indicating strong liquidity.
• The company reported net income of $50.363 million and basic and diluted EPS of $0.23 for the quarter ended September 30, 2026, according to its 10-Q filing dated October 29, 2026.
• The company’s common stock is listed on NYSE American and has experienced a 1-for-5 reverse stock split on February 20, 2026.
• Risk factors disclosed include concentration of digital assets in self-custody with potential security risks, and anti-dilution provisions in warrants that could affect stock price and listing status on NYSE American [S2].
• Recent business news coverage includes industry peers and sector-related companies but no direct recent news specifically about NovaBay Pharmaceuticals [N1][N2][N3][N4][N5][N6][N7][N8].